Chemotherapy Plus Best Supportive Care Versus Best Supportive Care in Patients with Non-small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Apr 5

PMID 23555583

Citations 16

Authors

Chenxi Zhong

Hongcheng Liu

Liyan Jiang

Wei Zhang

Feng Yao

Affiliations

Soon will be listed here.

Abstract

Background: The use of chemotherapy has been proposed to increase the effectiveness of best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC). Previous trials reported inconsistent findings regarding the efficacy and safety of chemotherapy on overall survival (OS) and treatment-related mortality. We performed a systematic review and meta-analysis to evaluate the effects of chemotherapy plus BSC versus BSC alone on survival of patients with NSCLC.

Methodology And Principal Findings: We systematically searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials for relevant literature. All eligible studies included patients with NSCLC who had received chemotherapy and BSC or BSC alone. All eligible studies measured at least 1 of the following outcomes: OS or treatment-related mortality. Overall, patients that received chemotherapy plus BSC had significant longer OS than those that received BSC alone (HR, 0.76; 95%CI, 0.69-0.84; P<0.001). Additionally, chemotherapy plus BSC as compared to BSC alone resulted in a 28% RR reduction (95%CI: 12-40; P = 0.001) in 6-month mortality, 11% RR reduction (95%CI: 8-15; P<0.001) in 12-month mortality, and 5% RR reduction (95%CI: 1-8; P = 0.02) in 2-year mortality. Toxicity was greater in patients that received chemotherapy plus BSC.

Conclusion/significance: Chemotherapy plus BSC increased the OS and reduced the 6-month, 12-month, and 2-year mortality of NSCLC patients.

Citing Articles

Transcriptomic and immunologic implications of the epithelial-mesenchymal transition model reveal a novel role of SFTA2 in prognosis of non-small-cell lung carcinoma.

Li N, Zhai Z, Chen Y, Li X Front Genet. 2022; 13:911801.

PMID: 36092941 PMC: 9458971. DOI: 10.3389/fgene.2022.911801.

Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients.

Kwan T, Chowdhury E Medicina (Kaunas). 2021; 57(11).

PMID: 34833470 PMC: 8618045. DOI: 10.3390/medicina57111252.

Virtual randomized study comparing lobectomy and particle beam therapy for clinical stage IA non-small cell lung cancer in operable patients.

Seo Y, Park W, Kim S, Kim D, Min B, Kim W J Radiat Res. 2021; 62(5):884-893.

PMID: 34218277 PMC: 8438263. DOI: 10.1093/jrr/rrab060.

Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition.

Baum P, Taber S, Erdmann S, Muley T, Kriegsmann M, Christopoulos P Cancers (Basel). 2021; 13(8).

PMID: 33920161 PMC: 8068959. DOI: 10.3390/cancers13081812.

Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma.

Sereno M, He Z, Smith C, Baena J, Das M, Hastings R Histopathology. 2020; 78(6):838-848.

PMID: 33155719 PMC: 8247971. DOI: 10.1111/his.14301.

References

Ganz P, Figlin R, Haskell C, La Soto N, Siau J . Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer. 1989; 63(7):1271-8. DOI: 10.1002/1097-0142(19890401)63:7<1271::aid-cncr2820630707>3.0.co;2-6. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View

. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2010; (5):CD007309. PMC: 11380090. DOI: 10.1002/14651858.CD007309.pub2. View

Belani C, Wu Y, Chen Y, Kim J, Yang S, Zhang L . Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol. 2011; 7(3):567-73. DOI: 10.1097/JTO.0b013e31823d4f9d. View

Wingo P, Cardinez C, Landis S, Greenlee R, Ries L, Anderson R . Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003; 97(12 Suppl):3133-275. DOI: 10.1002/cncr.11380. View

Rapp E, Pater J, Willan A, Cormier Y, Murray N, Evans W . Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988; 6(4):633-41. DOI: 10.1200/JCO.1988.6.4.633. View

Helsing M, Bergman B, Thaning L, Hero U . Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study.... Eur J Cancer. 1998; 34(7):1036-44. DOI: 10.1016/s0959-8049(97)10122-8. View

Anderson H, Hopwood P, Stephens R, Thatcher N, Cottier B, Nicholson M . Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000; 83(4):447-53. PMC: 2374661. DOI: 10.1054/bjoc.2000.1307. View

Cartei G, Cartei F, Cantone A, CAUSARANO D, Genco G, Tobaldin A . Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst. 1993; 85(10):794-800. DOI: 10.1093/jnci/85.10.794. View

10.

Ades A, Lu G, Higgins J . The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005; 25(6):646-54. DOI: 10.1177/0272989X05282643. View

11.

Ciuleanu T, Brodowicz T, Zielinski C, Kim J, Krzakowski M, Laack E . Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374(9699):1432-40. DOI: 10.1016/S0140-6736(09)61497-5. View

12.

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P . Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3,.... Lancet Oncol. 2012; 13(3):247-55. DOI: 10.1016/S1470-2045(12)70063-3. View

13.

Baggstrom M, Stinchcombe T, Fried D, Poole C, Hensing T, Socinski M . Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007; 2(9):845-53. DOI: 10.1097/JTO.0b013e31814617a2. View

14.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

15.

Woods R, Williams C, Levi J, Page J, Bell D, Byrne M . A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990; 61(4):608-11. PMC: 1971367. DOI: 10.1038/bjc.1990.135. View

16.

Souhami R . Chemotherapy in non-small cell bronchial carcinoma. Thorax. 1985; 40(9):641-5. PMC: 460162. DOI: 10.1136/thx.40.9.641. View

17.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

18.

Shepherd F . Chemotherapy for non-small cell lung cancer: have we reached a new plateau?. Semin Oncol. 1999; 26(1 Suppl 4):3-11. View

19.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

20.

Cohen M, Cortazar P, Justice R, Pazdur R . Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist. 2010; 15(12):1352-8. PMC: 3227931. DOI: 10.1634/theoncologist.2010-0224. View